Coapt Systems Launches Hydrelle

Coapt Systems has launched Hydrelle, a new FDA-approved hyaluronic acid-based dermal filler, for the treatment of facial wrinkles.

Hydrelle has been formulated with an anesthetic (lidocaine) for greater patient comfort, and to deliver rapid results comparable to other hyaluronic acid fillers, said the company.

In a randomized, controlled pivotal US study of 208 patients, Hydrelle was proven safe and effective. In a multi-center, international study, Hydrelle demonstrated patient and physician satisfaction, and filler effectiveness for up to one year.

David Barella, Executive Vice President of Global Marketing and Sales, Coapt Systems, said: “The Coapt Systems sales and marketing team is delighted to introduce Hydrelle to the facial aesthetic community throughout the US I believe that a long-lasting, more comfortable, and cost-effective dermal filler represents a valuable advantage to the millions of women and men that seek to improve their facial appearance every year.”

“Physicians will also enjoy the convenient, ready-to-use benefits that Hydrelle with lidocaine offers, without costly and labor intensive pre-injection mixing,” he added.